Table 3.
Predictors of subsequent treatment for non-transplant and transplant patients with NDMM
| Non-transplant patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| Overall (N = 22,062) | 6+ months follow-upa (n = 14,866) | 12+ months follow-upa (n = 11,619) | 24+ months follow-upa (n = 7233) | |||||
| Predictors of subsequent treatment (receiving LOT2+ vs. only LOT1) | Odds ratiob (95% CI) | P-valueb | Odds ratiob (95% CI) | P-valueb | Odds ratiob (95% CI) | P-valueb | Odds ratiob (95% CI) | P-valueb |
| Age at MM diagnosis, years | ||||||||
| < 65 | 0.90 (0.84–0.97) | 0.0035 | 1.01 (0.92–1.11) | 0.7975 | 1.09 (0.98–1.22) | 0.1154 | 1.08 (0.94–1.25) | 0.2889 |
| 65–74 | Reference | Reference | Reference | Reference | ||||
| 75–84 | 0.86 (0.80–0.91) | < 0.0001 | 0.84 (0.77–0.90) | < 0.0001 | 0.86 (0.78–0.94) | 0.0010 | 0.91 (0.80–1.03) | 0.1173 |
| ≥ 85 | 0.47 (0.42–0.53) | < 0.0001 | 0.45 (0.40–0.52) | < 0.0001 | 0.44 (0.38–0.52) | < 0.0001 | 0.55 (0.44–0.69) | < 0.0001 |
| Sex, male | 0.96 (0.91–1.01) | 0.1494 | 1.03 (0.96–1.10) | 0.3843 | 1.08 (1.00–1.17) | 0.0509 | 1.10 (0.99–1.22) | 0.0871 |
| Comorbidities during 180 days prior to index MM diagnosis | ||||||||
| Cardiovascular disordersc | 0.84 (0.79–0.90) | < 0.0001 | 0.84 (0.78–0.91) | < 0.0001 | 0.83 (0.76–0.91) | < 0.0001 | 0.88 (0.78–1.00) | 0.0479 |
| Liver disease | 0.91 (0.80–1.04) | 0.1573 | 0.88 (0.75–1.03) | 0.1195 | 0.88 (0.72–1.06) | 0.1784 | 0.73 (0.57–0.94) | 0.0149 |
| Pulmonary circulation disorders | 0.75 (0.66–0.86) | < 0.0001 | 0.76 (0.64–0.89) | 0.0009 | 0.75 (0.62–0.91) | 0.0030 | 0.79 (0.60–1.04) | 0.0924 |
| Renal impairment | 0.91 (0.85–0.98) | 0.0112 | 0.91 (0.83–0.99) | 0.0225 | 0.97 (0.88–1.07) | 0.5209 | 0.94 (0.82–1.07) | 0.3363 |
| Transplant patients | ||||||||
| Overall (N = 2763) | 6+ months follow-upa (n = 2595) | 12+ months follow-upa (n = 2245) | 24+ months follow-upa (n = 1535) | |||||
| Predictors of subsequent treatment (receiving LOT2+ vs. only LOT1) | Odds ratiob (95% CI) | P-valueb | Odds ratiob (95% CI) | P-valueb | Odds ratiob (95% CI) | P-valueb | Odds ratiob (95% CI) | P-valueb |
| Age at MM diagnosis, years | ||||||||
| < 65 | 1.05 (0.87–1.27) | 0.5989 | 1.13 (0.92–1.38) | 0.2421 | 1.30 (1.03–1.65) | 0.0288 | 1.40 (1.02–1.91) | 0.0380 |
| 65–74 | Reference | Reference | Reference | Reference | ||||
| 75–84 | 1.21 (0.69–2.12) | 0.5059 | 1.00 (0.57–1.77) | 0.9953 | 1.11 (0.55–2.23) | 0.7656 | 0.75 (0.34–1.67) | 0.4855 |
| ≥ 85 | – | – | – | – | – | – | – | – |
| Sex, male | 1.20 (1.00–1.44) | 0.0543 | 1.18 (0.97–1.45) | 0.1029 | 1.18 (0.93–1.49) | 0.1650 | 1.27 (0.94–1.73) | 0.1218 |
| Comorbidities during 180 days prior to index MM diagnosis | ||||||||
| Cardiovascular disordersc | 0.85 (0.68–1.08) | 0.1790 | 0.86 (0.67–1.11) | 0.2423 | 0.88 (0.66–1.17) | 0.3664 | 0.99 (0.68–1.45) | 0.9528 |
| Liver disease | 0.56 (0.39–0.81) | 0.0017 | 0.49 (0.34–0.70) | 0.0001 | 0.48 (0.31–0.73) | 0.0005 | 0.41 (0.23–0.72) | 0.0020 |
| Pulmonary circulation disorders | 0.70 (0.39–1.27) | 0.2466 | 0.60 (0.33–1.09) | 0.0926 | 0.51 (0.26–1.01) | 0.0520 | 0.36 (0.14–0.90) | 0.0281 |
| Renal impairment | 0.79 (0.62–1.02) | 0.0668 | 0.71 (0.54–0.92) | 0.0099 | 0.74 (0.55–1.01) | 0.0601 | 0.58 (0.40–0.86) | 0.0059 |
CI Confidence interval, LOT Line of therapy, MM Multiple myeloma
aMonths of follow-up were calculated from the start of the first line of treatment until either the end of insurance eligibility (for SEER and OPTUM™ Commercial)
bOdds ratios and p-values were computed using a logistic regression
cCardiovascular disorders include cardiac arrythmia, congestive heart failure, complicated hypertension, and valvular disease